Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Biochemical Relapse of Prostate Cancer

NCT07860047 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT07860047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07860047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Biochemical Relapse of Prostate Cancer
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Recruiting
Start date
September 24, 2026
Completion date
March 31, 2030
Enrollment
84 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer